id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-302528-wmxw9e0c	Mitchell, Stephanie L.	Evaluation of the COVID19 ID NOW EUA Assay	2020-05-15		.txt	text/plain	909	62	56	• ID NOW EUA SARS-CoV-2 assay had an overall agreement of 78.7% when compared to the standard of care reference methods. While most of the SARS-CoV-2 EUA assays for molecular detection must be performed in moderate-to high-complexity clinical laboratories, a few are authorized as point-of-care devices, such as the Abbott ID NOW. In addition to clinical laboratories, this assay can be performed by trained non-laboratory personnel in patient care settings such an Emergency Departments, physician's offices or pharmacies, potentially bringing diagnostic testing for SARS-CoV-2 closer to the patient (1). Among the marketing information for this new assay, potential advantages include its reported sensitivity (stated limit of detection (LOD) of 125 genome equivalents/ml) and run time (detection of SARS-CoV-2 RNA as early as five minutes and a negative result in thirteen minutes). Residual positive and negative nasopharyngeal patient samples collected in VTM were tested using the ID NOW EUA assay.	./cache/cord-302528-wmxw9e0c.txt	./txt/cord-302528-wmxw9e0c.txt